Characterizing interspecies uncertainty using data from studies of anti-neoplastic agents in animals and humans

Toxicology and Applied Pharmacology

Volumn 233, Issue 1, 2008, Pages 64-70

  Price, Paul S ^a   Keenan, Russell E ^b   Swartout, Jeffrey C ^c  

^a DOW CHEMICAL COMPANY   (United States)

^b AMEC FOSTER WHEELER   (United States)

^c U S ENVIRONMENTAL PROTECTION AGENCY   (United States)

Author keywords

Interspecies; Reference dose; Risk characterization; Uncertainty factors

Indexed keywords

5,6 DIHYDROAZACITIDINE; ANTINEOPLASTIC AGENT; BUSULFAN; CARBOPLATIN; CHLORMETHINE; CHLORMETHINE N OXIDE; CYCLOPHOSPHAMIDE; DACTINOMYCIN; DIACETOXYSCIRPENOL; FLOXURIDINE; FLUDARABINE; FLUOROURACIL; GALLIUM NITRATE; HOMOHARRINGTONINE; MELPHALAN; MERCAPTOPURINE; METHOTREXATE; MITHRAMYCIN; MITOGUAZONE; MITOMYCIN C; N METHYLFORMAMIDE; PACTAMYCIN; PIPERAZINEDIONE; SPARFOSIC ACID; THALICARPINE; THIOTEPA; TRICIRIBINE; UNINDEXED DRUG; VINBLASTINE; VINCRISTINE;

ARTICLE; DATA ANALYSIS; DOG; DRUG INFORMATION; HUMAN; HUMAN VERSUS ANIMAL COMPARISON; MONKEY; MOUSE; NONHUMAN; RAT; SPECIES DIFFERENCE; TOXICITY TESTING; UNCERTAINTY;

ANIMALS; ANTINEOPLASTIC AGENTS; BODY WEIGHT; DATABASES, FACTUAL; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; HAPLORHINI; HUMANS; MICE; RATS; SPECIES SPECIFICITY; UNCERTAINTY;

ANIMALIA; CANIS FAMILIARIS; MUS; RATTUS;

EID: 55649120017     PISSN: 0041008X     EISSN: 10960333     Source Type: Journal    
DOI: 10.1016/j.taap.2008.03.026     Document Type: Article

References (45)

1. Andersen M.E., Clewell H., and Krishnan K. Tissue dosimetry, pharmacokinetic modeling, and interspecies scaling factors. Risk Anal. 15 4 (1995) 533-553
2. ATSDR. Minimal risk levels for priority substances and guidance for derivation. 61. Fed. Regist. 101 (1996) 25873-25882
3. Baird S.J.S., Cohen J.T., Graham J.D., Shlyakhter A.I., and Evans J.S. Noncancer risk assessment: a probabilistic alternative to current practice. Hum. Ecol. Risk Assess. 2 (1996) 79-102
4. Barnes D.G., and Dourson M.L. Reference dose (RfD): description and use in health risk assessment. Regul. Toxicol. Pharmacol. 8 (1988) 471-486
5. Bokkers B.G.H., and Slob W. Deriving a data-based interspecies assessment factor using the NOAEL and the benchmark dose approach. Crit. Rev. Toxicol. 37 (2007) 355-373
6. Bosgra S., Bos P.M.J., Vermeire T.G., Luit R.J., and Slob W. Probabilistic risk characterization: an example with di(2-ethylhexyl) phthalate. Reg. Toxicol. Pharmacol. 43 (2005) 104-113
7. Brand K.P., Catalano P.J., Hammitt J.K., Rhomberg L., and Evans J.S. Limitations in empirical extrapolation studies the case of the BMD ratios. Risk Anal. 21 4 (2001) pages
8. Brand K.P., Rhomberg L., and Evans J.S. Estimating non cancer uncertainty factors: are ratios of NOAELs informative. Risk Anal. 19 2 (1999) pages
9. Carlson-Lynch H., Price P.S., Swartout J.C., Dourson M.L., and Keenan R.E. Application of quantitative information on the uncertainty in the RfD to noncarcinogenic risk assessments. HERA 5 3 (1999) 527-547
10. Dourson M.L. Methodology for establishing oral reference doses (RfDs). In: Mertz W., Abernathy C.O., and Olin S.S. (Eds). Risk Assessment of Essential Elements (1994), ILSI Press, Washington, D.C.
11. Dourson M.L., and Stara J.F. Regulatory history and experimental support of uncertainty (safety) factors. Regul. Toxicol. Pharmacol. 3 (1983) 224-238
12. Efron B., and Tibshirani R.J. An introduction to the bootstrap. Monographs on Statistics and Applied Probability 57 (1993), Chapman & Hall, New York
13. EFSA. Scientific Colloquium Summary Report 21-22 March 2006 - Parma, Italy, Development of Food-Based Dietary Guidelines European Food Safety Authority (2007)
14. European Union. Registration Evaluation Authorization of Chemicals (REACh) (2007)
15. Evans J.S., Rhomberg L., Williams P.L., Wilson A., and Baird S.J. Reproductive and developmental risks from ethylene oxide: a probabilistic characterization of possible regulatory thresholds. Risk Anal. 21 (2001) 697-717
16. Freireich E.J., Gehan E.A., Rall D.P., Schmidt L.H., and Skipper H.E. Quantitative comparison of toxicity of anti-cancer agents in mouse, rat, hamster, dog, monkey, and man. Cancer Chemotherapy Rep. 50 (1966) 219-244
17. Goldsmith M.A., Slavik M., and Carter S.K. Quantitative prediction of drug toxicity in humans from toxicology in small and large animals. Cancer Res. 35 (1975) 1354-1364
18. Grieshaber C.K., and Marsoni S. Relation of pre-clinical toxicology to findings in early clinical trials. Cancer Treatment Rep. 70 (1986) 65-72
19. Kalberlah F., Föst U., and Schneider K. Time extrapolation and interspecies extrapolation for locally acting substances in case of limited toxicological data. Ann. Occup. Hyg. 46 2 (2002) 175-185
20. Kalberlah F., Schneider K., and Schuhmacher-Wolz U. Uncertainty in toxicological risk assessment for non-carcinogenic health effects. Reg. Toxicol. Pharmacol. 37 (2003) 92-104
21. Kodell R.L., and Chen J.J. On the use of hierarchical probabilistic models for characterizing and managing uncertainty in risk/safety assessment. Risk Analysis 27 2 (2007)
22. Nair R.S., Sherman J.H., Stevens M.W., and Johannsen F.R. Selecting a more realistic uncertainty factor: reducing compounding effects of multiple uncertainties. Hum. Ecol. Risk Assess. 1 (1995) 576-589
23. Nauman B.D., and Weideman P.A. Scientific basis for uncertainty factors used to establish occupational exposure limits for pharmaceutical active ingredients. Hum. Ecol. Risk Assess. 1 (1995) 590-613
24. Nessel C.S., Lewis S.C., Stauber K.L., and Adgate J.L. Subchronic to chronic exposure extrapolation: toxicologic evidence for a reduced uncertainty factor. Hum. Ecol. Risk Assess. 1 (1995) 516-526
25. Paxton J.W., Kim S.N., and Whitfield L.R. Pharmacokinetic and toxicity scaling of the antitumor agents amsacrine and CI-921, a new analogue, in mice, rats, rabbits, dogs, and humans. Cancer Res. 50 (1990) 2692-2697
26. Price P.S., Keenan R.E., Swartout J.C., Gillis C.A., Carlson-Lynch H., and Dourson M.L. An approach for modeling noncancer dose responses with an emphasis on uncertainty. Risk Anal. 17 (1997) 427-437
27. Price P.S., Keenan R.E., and Schwab B.W. Defining the interindividual (intraspecies) uncertainty factor. Hum. Ecol. Risk Assess. 5 (1999) 1023-1033
28. Rhomberg L.R., and Wolff S.K. Empirical scaling of single oral lethal doses across mammalian species based on a large database. Risk Anal. 18 6 (1998) 741-753
29. Rhomberg L.R., and Lewandowski T.A. Methods for identifying a default cross-species scaling factor. Gradient Corporation, Prepared under Contract 3W-0477-NASX for: Risk Assessment Forum U.S. Environmental Protection Agency 1200 Pennsylvania Avenue, N.W. Washington, D.C. 20460 April 2 (2004)
30. Rozensweig M., Von Hoff D.D., Staquet M.J., Schein P.S., Penta J.S., Goldin A., Muggia F.M., Freireich E.J., and DeVita V.T. Animal toxicology for early clinical trials with anticancer agents. Cancer Clin. Trials 4 (1981) 21-28
31. Schein P., Davis R.D., Carter S., Newman J., Schein D.R., and Rall D.P. The evaluation of anticancer drugs in dogs and monkeys for the prediction of qualitative toxicities in man. Clin. Pharmacol. Therap. 11 (1979) 3-40
32. Schneider K., Oltmanns J., and Hassauer M. Allometric principles for interspecies extrapolation in toxicological risk assessment - empirical investigations. Reg. Toxicol. Pharmacol. 39 (2004) 334-347
33. Slob W., and Pieters M.N. A Probabilistic Approach for Deriving Acceptable Human Intake Limits and Human Health Risks from Toxicological Studies: General Framework (1997), National Institute of Public Health and the Environment, The Netherlands Report no. 620110 005
34. Slob W., and Pieters M.N. A probabilistic approach for deriving acceptable human intake limits and human health risks from toxicological studies: general framework. Risk Anal. 18 6 (1998) pages
35. Storer B.E. Design and analysis of phase I clinical trials. Biometrics 45 3 (1989) 25-37
36. Swartout J.C., Price P.S., Dourson M.L., and Keenan R.E. A probabilistic framework for the reference dose. Risk Anal. 18 3 (1998) 271-282
37. Travis C.C., and White R.K. Interspecies scaling of toxicity data. Risk Anal. 8 (1988) 119-125
38. U.S. Environmental Protection Agency (USEPA), 1988. Integrated Risk Information System (IRIS); Background Document 1. National Center for Environmental Assessment, Cincinnati Office, Cincinnati, Ohio.
39. U.S. Environmental Protection Agency (USEPA), 2007. Integrated Risk Information System (IRIS). Office of Research and Development, National Center for Environmental Assessment, Washington, DC. Online http://www.epa.gov/iris.
40. Van der Voet H., and Slob W. Integration of probabilistic exposure assessment and probabilistic hazard characterization. Risk Anal. 27 2 (2007) pages
41. Vermeire T., Stevenson H., Pieters M.N., Rennen M., Slob W., and Hakkert B.C. Assessment Factors for Human Health Risk Assessment: A Discussion Paper Critical Reviews in Toxicology 29(5) (1999) 439-490
42. Vermeire T., Stevenson H., Pieters M.N., Rennen M., Slob W., and Hakkert B.C. Probabilistic assessment factors for human health risk assessment: a practical guide. National Institute of Public Health and the Environment (RIVM), RIVM Report 601516 005, TNO report V3489 (2001)
43. Watanabe K., Bois F.Y., and Zeise L. Interspecies extrapolation: a reexamination of acute toxicity data. Risk Anal. 12 (1992) 301-310
44. Weil C.S. Guidelines for experiments to predict the degree of safety of a material for man. Toxicol. Appl. Pharmacol. 21 (1972) 194-199
45. Weil C.S., and McCollister D.D. Relationship between short- and long-term feeding studies in designing an effective toxicity test. Agric. Fd. Chem. 11 (1963) 486-491